ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,173.20
      1.85%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.795
      0.20%
      Bitcoin
      59,086.08
      -0.06%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cocrystal Pharma Inc (COCP)

      7. Cocrystal Pharma Inc (COCP) News

      COCP

      Cocrystal Pharma (COCP)

      Cocrystal Pharma Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:COCP
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      05/01/20248:00AMGlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
      03/28/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
      03/19/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ANASDAQ:COCPCocrystal Pharma Inc
      03/01/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      01/08/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      01/04/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      01/04/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesNASDAQ:COCPCocrystal Pharma Inc
      01/02/20249:53AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COCPCocrystal Pharma Inc
      12/21/20235:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      12/06/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      12/06/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANASDAQ:COCPCocrystal Pharma Inc
      12/04/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      11/29/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      11/29/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
      11/27/20238:00AMGlobeNewswire Inc.Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:COCPCocrystal Pharma Inc
      11/13/20238:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      11/13/20238:01AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
      11/13/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
      11/09/20238:00AMGlobeNewswire Inc.Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
      10/31/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      10/31/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
      09/28/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and CoronavirusNASDAQ:COCPCocrystal Pharma Inc
      09/05/20238:00AMGlobeNewswire Inc.Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:COCPCocrystal Pharma Inc
      08/16/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
      08/14/20238:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
      08/14/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
      08/08/20238:00AMGlobeNewswire Inc.Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus LeadNASDAQ:COCPCocrystal Pharma Inc
      07/20/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
      07/20/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
       Showing the most relevant articles for your search:NASDAQ:COCP